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Intracranial/intracerebral hemorrhage (ICH) is a leading cause of death and disability in peo-
ple with traumatic brain injury (TBI) and stroke. No proven drug is available for ICH. Panax
notoginseng (total saponin extraction, PNS) is one of the most valuable herb medicines
for stroke and cerebralvascular disorders in China. We searched for randomized controlled
clinical trials (RCTs) involving PNS injection to treat cerebral hemorrhage for meta-analysis
from various databases including the Chinese Stroke Trials Register, the trials register of
the Cochrane Complementary Medicine Field, the Cochrane Central Register of Controlled
Trials, MEDLINE, Chinese BioMedical disk, and China Doctorate/Master Dissertations Data-
bases. The quality of the eligible trials was assessed by Jadad’s scale. Twenty (20) of
the 24 identified randomized controlled trials matched the inclusive criteria including 984
ICH patients with PNS injection and 907 ICH patients with current treatment (CT). Com-
pared to the CT groups, PNS-treated patients showed better outcomes in the effectiveness
rate (ER), neurological deficit score, intracranial hematoma volume, intracerebral edema
volume, Barthel index, the number of patients died, and incidence of adverse events. Con-
clusion: PNS injection is superior to CT for acute ICH. A review of the literature shows that
PNS may exert multiple protective mechanisms against ICH-induced brain damage includ-
ing hemostasis, anti-coagulation, anti-thromboembolism, cerebral vasodilation, invigorated
blood dynamics, anti-inflammation, antioxidation, and anti-hyperglycemic effects. Since vit-
amin C and other brain cell activators (BCA) that are not considered common practice were
also used as parts of the CT in several trials, potential PNS and BCA interactions could exist
that may have made the effect of PNS therapy less or more impressive than by PNS therapy
alone. Future PNS trials with and without the inclusion of such controversial BCAs as part
of the CT could clarify the situation. As PNS has a long clinical track record in Asia, it could
potentially become a therapy option to treat ICH in the US and Europe. Further clinical trials
with better experimental design could determine the long-term effects of PNS treatment
for TBI and stroke.
Keywords: notoginsenosides, botanical medicine, nutraceuticals, TBI and stroke recovery, randomized controlled
clinical trials, hemostasis, anti-coagulation, pharmacological mechanisms
INTRODUCTION
Traumatic brain injury (TBI) is a leading cause of death and dis-
ability in young people (1). Every year approximately 1.5 million
people die and at least 10 million people are hospitalized after TBI
(2). The incidence of TBI fatality and disability rates are higher in
developing countries than in developed countries (3).
Secondary brain damage due to continued intracranial and
intracerebral bleeding and hemorrhage swelling is a common
cause of morbidity and mortality (4, 5). In one clinical trial, 56%
of the patients with mild, moderate and severe TBI developed
intracranial hemorrhage (6). Another study showed that 51%
of TBI patients developed progressive intracranial/intracerebral
hemorrhage (ICH), and hemorrhage expansion during the first
24–48 h after hospital admission (7). Prognostic studies have
shown that ICH is associated with increased mortality and dis-
ability 6 months after injury (8, 9). One recent survey reported
that TBI patients who developed ICH showed a 10-fold increase
in stroke incidence 3 months after the injury when compared to
TBI patients without ICH (10).
Acute intracerebral hemorrhage (AICH) accounts for only
about 10% of the people with stroke, and is the most lethal
form of stroke compared to the ischemic stroke. Thus, ICH is
among the most devastating disorders and a leading cause of dis-
ability and mortality of people with severe stroke, hypertension,
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and TBI (11). During the last decade, the incidence of ICH has
increased steadily in Asian countries (12) and it accounts for ~20%
and ~10% of strokes in low-middle and high income countries,
respectively (13).
So far, few proven therapies exist for ICH. Hematoma expan-
sion, perihematomal edema with increased intracranial pressure,
intraventricular extension of hemorrhage with hydrocephalus,
seizures, venous thrombotic events, hyperglycemia, increased
blood pressure, fever, and infections are among the complica-
tions of ICH as recently reviewed by Balami and Buchan (14).
Current treatment of ICH is supportive and life-sustaining rather
than a complete cure that aims to limit secondary brain dam-
age and associated complications (15, 16). Considering the very
limited therapeutic options for patients with ICH, recent studies
suggest that evidence-based alternative and complimentary med-
icines could be effective in reducing the adverse effects early in
the course of ICH and in improving its prognosis as found in the
treatment of cerebral ischemia (17).
Panax notoginseng [(Burk.) F.H. Chen] (also called Sanqi in
Chinese), is one of the most valuable Chinese herbal medi-
cine. P. notoginseng is a perennial plant, mainly grown in the
high mountain areas of Southwest China. Its roots are har-
vested after 3–5 years of growth (Figure 1). P. notoginseng has
numerous hematological and pharmacological effects, which
include regulation of platelet aggregation and platelet free cal-
cium levels, reducing blood viscosity, improving local blood
supply and circulation to end stasis, cerebral vasodilation, anal-
gesic, hypolipidemic, hemostatic, anti-edema, anti-hyperglycemia,
antioxidation, anti-inflammation, and anti-apoptosis (18, 19).
P. notoginseng saponins extract (PNS) ameliorate learning and
memory deficits in animals (20–26), probably by inhibiting oxida-
tive stress and apoptosis and by stimulating neurogenesis (21, 22,
27–33). PNS is effective against ICH, transient focal ischemia,
and cerebral infarction probably in part through improved brain
blood circulation and energy metabolism (34–38). P. notogin-
seng has been used alone and as a key tonic ingredient in
many other patent Chinese medicine for treatment of a vari-
ety of health conditions and has been proved to be effective
in animal models of cerebral ischemia/reperfusion injury, arter-
ial thrombosis, cardiovascular disorders, Alzheimer disease, dia-
betes and obesity, erectile dysfunction, neurodegeneration, neu-
roinflammation, oxidative stress, neurotoxicity, organ injury, and
cancer (38–47).
The ability of notoginseng to normalize hemorheological para-
meters is due to the presence of multiple active compounds
including different ginsenosides and notoginsenosides, some of
which appear to have similar yet differential effects. Ginseno-
sides Rg1 and Rb1, and notoginsenoside R1 are the main active
ingredients present in high concentrations in PNS, which contains
more than 20 different ginsenosides and notoginsenosides (48–
55). Purified and patented PNS under different trade names, i.e.,
Xuesaitong (51, 56–59), Xueshuantong (60), and Lulutong have
been approved for treatment of stroke and other cerebral disorders
in China. Intravenous injection of PNS has been developed for crit-
ical care because orally administered PNS has a low permeability,
poor intestinal absorption, and bioavailability (51, 61, 62) due to
the relative large sugar molecular mass (>500 Da), high molecular
flexibility, high hydrogen binding capacity, and low lipophilicity.
FIGURE 1 | Panax notoginseng (P. notoginseng, Sanqi): clockwise from top left: in cultivation, the roots, artistic drawing a Sanqi plant, the main
chemical ingredients of PNC: notoginsenoside R1, ginsenosides Rb1, and Rg1.
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In vivo studies showed marked variability of Rb1 bioavailability
among different administration routes to rats: i.v. (intravenous)
(100%)> p.v. (portal venous) (59.49%)> i.d. (intra-duodenal)
(2.46%)> p.o. (peroral) (0.64%) (63). After absorption, PNS has
a long residual time, but individual ginsenosides and notogin-
senosides vary in their elimination rate. For example, the half-life
is much longer and peak concentration higher for ginsenoside Rb1
than that for ginsenoside Rg1 and notoginsenoside R1, due to the
slower clearance and longer residence time of Rb1 (61, 63–67). In
fact, ginsenoside Rb1 is considered a pharmacokinetic marker of
PNS (67).
Multiple clinical studies have been conducted in China in recent
years to explore the use of PNS injection in the treatment of
cerebral hemorrhage and ICH. These studies have yet to be system-
atically evaluated for the efficacy and safety to provide evidence
and guidance for further clinical application of PNS for cere-
bral hemorrhage. Because many of these trials were reported in
un-indexed Chinese medical journals, the international research
community may not have access to these findings. In this study, we
reviewed randomized controlled clinical trials (RCTs) published in
Chinese journals that involved PNS injection treatment for ICH.
The results suggest that PNS injection has a wide range of differ-
ent protective mechanisms and is a better treatment than current
treatments for ICH.
MATERIALS AND METHODS
INCLUSIVE AND EXCLUSIVE CRITERIA
Only RCTs that included a comparison of the efficacy and safety
of P. notoginseng saponin (PNS) injection treatment with that
of current treatment (CT) in patients with AICH resulted from
hypertension or wind stroke were included. The diagnostic crite-
ria of acute ICH in trials were in accordance with the criteria of
diagnosis of various types of cerebrovascular disease updated at
the 4th Annual Conferences of Chinese Society of Neurology (68):
subjects should not suffer from secondary AICH or other diseases
such as hematologic diseases, intracranial aneurysms, intracranial
tumors, cerebral arteries, venous malformations, severe comas,
and cardiac, hepatic, or renal diseases. There was no restriction
on race, but the majority of patients were thought to be of the
Chinese Han ethnic group. The PNS intervention is defined as
intravenous drip of the commercially available PNS preparations
that are approved by Chinese Food and Drug Administration
(CFDA) for clinical use alone, or in combination with other rou-
tine therapies for subjects in the treatment groups. The control
ICH subjects received current treatment other than PNS treat-
ment. The outcome measures included the effectiveness rate (ER),
neurological deficit score (NDS), intracerebral hematoma vol-
ume (IHV), intracerebral edema volume (IEV), Barthel index
(BI), and number of patients died (NDP), as well as incidence
of adverse events after treatments with PNS or CT, respectively.
The BI is an interviewer-based disability profile scale developed
by D.W. Barthel in 1965 to assess physical functions, specifi-
cally self-care abilities and ambulation (e.g., stair climbing) in
10 areas, including bowel and bladder control. The patient is
scored from 0 to 15 points in various categories, depending on
his or her need for help, such as in feeding, bathing, dressing, and
walking.
SEARCH STRATEGY
The search strategy was developed by modifying the reported
strategies used for herbal medicines in a Cochrane review (69).
We retrieved the literatures of relevant clinical trials by electronic
searching and by hand searching, regardless of language or pub-
lication status. Many electronic databases were searched, includ-
ing the Chinese Stroke Trials Register, the trials register of the
Cochrane Complementary Medicine Field, the Cochrane Central
Register of Controlled Trials, MEDLINE, CINAHL, AMED, Chi-
nese BioMedical disk, Wanfang Chinese Scientific Journal Data-
base, VIP, China National Knowledge Infrastructure, Traditional
Chinese Medicine Database, Chinese Medical Current Contents,
China Doctorate/Master Dissertations Full-Text Databases, and
China Proceedings of Conference Databases. The reference lists
of retrieved papers were further scanned for any possible titles
matching the inclusive criteria. A hand search with an emphasis
on relevant journals pertaining to stroke, senile disease, neurol-
ogy, complementary, and alternative medicine was carried out to
explore entities matching the inclusive criteria among periodicals,
journals, and symposium abstracts found in libraries of Guangxi
Chinese Medical University (date of last search: December, 2013).
DATA EXTRACTION
Full-text articles of each potential eligible trial were retrieved and
assessed by two independent reviewers (Dongying Xu and Ping
Huang) to determine if the articles should be recruited and further
analyzed according to the inclusive and exclusive criteria. Missing
information was sought by contacting the article authors. A data
abstraction form was used to summarize key information from
included trials, and key information was extracted by one reviewer
and confirmed by the other. Any disagreements were resolved by
discussion.
DATA ANALYSIS
The meta-analysis was carried out by using Revman 5.3 software
(Cochrane Collaboration) to combine and analyze the data from
the individual trials. The statistical validity of combining various
trials was assessed by examining the homogeneity of outcomes
from trials using a Q-test (Mantel–Haenszel Chi-square test). The
results of the combined trials were calculated with random or
fixed-effect models. The measurements of each category’s data
were evaluated by a weighted mean difference (WMD) or odd ratio
(OR), and by 95% confidence intervals (95% CI). The method-
ological quality of all included trials was assessed by Jadad’s scale
that evaluated randomization, double blinding, and dropout rate
of the trials by ranking them with 1–5 points. The trials that
scored with 1 or 2 points were considered low-quality trials, while
those that scored with 3–5 points were considered high-quality
trials (70).
RESULTS
EXCLUDED AND INCLUDED TRIAL
The literature search yielded a total of 24 RCTs conducted in China
that treated acute intracerebral hemorrhagic patients with intra-
venous drip of PNS. However, four of these trials were excluded as
they did not match the inclusive criteria. Specifically, they are (1)
no-comparison made between PNS and RT in trials (two trials)
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and (2) no or unclear measurement report in trials (two trials).
Therefore, only 20 trials published in Chinese medical journals,
with 1,891 ICH patients that met the study criteria, were included
for analysis (71–90).
The characteristics of the patients are shown in Table 1. The
trials’ size varied from 24 to 200 participants, with an average of
46 patients per trial. All of the patients are adults ranged from 24
to 92 years old with more males than females included (62% males
vs. 38% females). Hemorrhage/ICH duration was reported in 13
trials, ranging from 4 h to 20 days. The main causes of intracere-
bral hemorrhage were wind stroke (15 trials) and hypertension (2
trials) (Table 1).
The classification of the patients (sites of bleeding) is shown
in Table 2. Of these, 984 ICH patients received PNS injection
treatments that lasted between 10 and 70 days, and 907 patients
received current treatments (Table 2). Of the PNS injection treat-
ments, 6 trials used Xuesaitong PNS freeze-dry powder injections
(72, 73, 77–79, 85), 7 trials used Xuesaitong injections (74, 75, 84,
86–88, 90), 5 trials used Xueshuantong injections (76, 80, 81, 83,
89), one trial used Lulutong injections (71), and one trial used
Sanqi Zaogan injection powder (82). For the CT control groups,
dehydration, control of intracranial pressure, anti-hypertensive
treatment, symptomatic treatment, neurotrophy medicine, and
brain cell activators (BCA) were used. Mannitol, glycerol, and/or
ructose injection was used for dehydration (Table 2).
OUTCOME MEASUREMENT
For evaluating the therapeutic and adverse effects of the PNS treat-
ment and the control groups, the outcome assessment of this study
was focused on the ER, NDS, intracerebral hematoma volume
(IHV), IEV, BI, and the NDP. The incidence of adverse events
after treatments was also evaluated. Thirteen trials reported the
number of improved patients. Six trials reported NDS. Eight trials
reported intracerebral hematoma volume. Three trials reported
intracranial edema volume. Two trials reported BI, and six trials
reported the NDP.
META-ANALYSIS ON PNS EFFICACY
Sites of bleeding
There were 15 trials involving 687 ICH patients in the PNS group
and 583 patients in the CT group (total of 1,270 ICH patients)
that provided detailed descriptions of the bleeding sites includ-
ing (unilateral and/or bilateral) the basal ganglia, external capsule,
internal capsule, frontal lobe, medial occipital lobe, arietal lobe,
cerebellum, brainstem, ventricles, and supratentorial hemorrhage
(Table 3). Among them, the basal ganglia region was the most
common site of hemorrhage, accounting for 45.85% (315/687) of
patients in the PNS group, and 41.51% (242/583) of patients in
the CT group.
Effectiveness rate
By using the fixed-effect model, Figure 2 shows the results of meta-
analyses on the ER, comparing the therapeutic effect of PNS injec-
tion with that of the CT. A total of 13 trials reported the effect rate,
which was categorized into three subgroups by the evaluating time:
(1) 7 trials assessed the ER at the end of 2 weeks of treatment, (2) 2
trials assessed the rate at the end of 3 weeks, and (3) 5 trials assessed
the rate at the end of 4 weeks. There was no significant heterogene-
ity among these three subgroups (P = 0.47). The total overall effect
showed significant statistical difference in ER between the PNS and
CT groups (OR= 2.70; 95% CI= 2.16, 3.38; P < 0.00001). There
were significant differences in ER between PNS and CT groups
assessed at 2 weeks (OR= 2.73; 95% CI= 1.92, 3.88; P < 0.00001),
3 weeks (OR= 2.43; 95% CI= 1.54, 3.83; P = 0.0001), and 4 weeks
(OR= 2.87; 95% CI= 1.97, 4.18; P < 0.00001) after the start of
treatment. No significant heterogeneity was presented in the analy-
ses of the data (P = 0.55, 0.61, and 0.13) in the three subgroups,
respectively. Thus, ICH patients with PNS treatment showed a
better therapeutic ER than those in the CT group.
Neurological deficit score
Neurological deficit score is an important index for the diagno-
sis of symptom severity and functional recovery of the patients
(91). Six of the selected trials reported NDS in this study, with
three of them showing NDS (74, 77, 86) at 7, 15, 21, 28, and
30 days after PNS treatment (Figure 3). No significant differences
in NDS were found between the PNS and CT groups at 7 (77) and
15 days (86). The results of 21 days are controversial, since one
trial showed no difference between the PNS and CT groups (74),
whereas the other showed a better NDS in the PNS group than
in the CT group (77). The NDS was significantly lower in PNS
group than that in CT group at 28 days (86) and 40 days (74) after
the treatment (P < 0.05,P < 0.01, respectively). No heterogeneity
(P = 0.48) was found in the NDS. When all data were combined,
the results showed significantly reduced NDS in PNS-treated ICH
patients than in ICH patients of the CT group (MD= 4.36; 95%
CI= 3.07, 5.65; P < 0.00001) (Figure 3).
Intracerebral hematoma volume
Of the 8 trials that reported IHV, 6 trials showed no differences
in IHV between the PNS and CT groups after 4–7 days of treat-
ment (82, 84, 85, 88, 89) (MD=−0.37; 95% CI=−1.60, 0.87;
P = 0.58) (Figure 4). Three trials (82, 84, 87) showed significant
improvement in IHV in the PNS group (about 25% less IHV) than
in the CT group at 10–14 days after the treatment (MD=−3.80;
95% CI=−5.87, −1.74; P = 0.0003). Four trials showed signif-
icantly smaller IHV values in the PNS group (about 40% less)
than in the CT group at 20–21 days after the treatment (74, 81, 84,
89) (MD=−4.82; 95% CI=−8.32, −1.33; P = 0.007). Another
4 trials showed significantly smaller IHV values in the PNS group
(about 50% less) than in the CT group at 28–40 days after the
treatment (74, 82, 85, 88) (MD=−5.15; 95% CI=−5.98,−4.33;
P < 0.00001). These results show a time-dependent effect of PNS
treatment on IHC, i.e., significant improvement in IHV occurs
after 21 days or more of PNS treatment, but not in the 1st week
of treatment (10–14 days, MD=−3.8;20–21 days, MD=−4.82;
28–40 days, MD=−5.15).
Intracerebral edema volume
Figure 5 shows the results of meta-analyses on IEV. Only three
trials (82, 85, 89) assessed IEV in ICH patients with PNS/CT treat-
ment 7 days after ICH onset. Two of the trials with a duration of
3–4 weeks showed significant differences in IEV between the PNS
and CT groups (65, 68). The other trial showed no significant dif-
ference between the two groups after 14 days of PNS injection due
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Table 1 | Baseline characteristics of each trial used in the
meta-analysis.
Authors Sample size (F/M) Average age
(range)
Disease
duration
Cause
Guo et al. (90) PNS: n=100 (40/60) 57.4 (30–70) ≥3D WS
CT: n=100 (38/62) 57.2 (31–69.5) WS
He et al. (89) PNS: n=12 (5/7) 69.20±14.32 ≤48H WS
CT: n=12 (4/8) 67.22±13.83 WS
Xu and
Dong (72)
PNS: n=42 (17/25) 60.63 (33–80) NR WS
RT: n=40 (17/23) 58.30 (34–79) WS
Li et al. (88) A:PNS: n=60 (25/35) (24–78) <24H WS
B:PNS: n=55 (22/33) (31–75) WS
C:CT: n=60 (26/34) (40–82) WS
Li and
Yang (73)
PNS: n=48 (13/35) 57.2±9.6
(45–75)
>20D WS
CT: n=44 (12/32) 56.8±9.4 (43–74) WS
Tian et al. (74) PNS: n=36 (16/20) 60.32±5.14 NR WS
CT: n=30 (16/14) 58.41±6.33 WS
Li and Sun (75) PNS: n=29 (9/20) 58.5±10.8
(31–82)
NR NR
CT: n=31 (9/22) 57.5±11.2 (33–81) NR
Xie et al. (76) PNS: n=24 (6/18) 61.1 (34–89) NR NR
CT: n=22 (6/16) 61.2 (35–92) NR
Chen et al. (77) PNS: n=22 (7/15) N/A 4H-12H WS
CT: n=21 (7/14) N/A WS
Dong and
Wang (78)
PNS: n=40 (16/24) 60.63 (33–80) NR HYTN
CT: n=38 (16/22) 58.3 (34–79) HYTN
Zhang
et al. (71)
PNS: n=65 (N/A) 57.6 (35–69) NR WS
CT: n=65 (N/A) 58.2 (36–70) WS
Zhou et al. (79) PNS: n=70 (24/46) 56.8±10.4
(35–78)
≤7D WS
CT: n=70 (27/43) 55.6±10.1
(33–79)
WS
Zheng (80) PNS: n=22 (N/A) N/A <72H N/A
CT: n=19 (N/A) N/A N/A
Tang et al. (81) PNS:n=63 (25/38) 62.2±14.6 3rd WS
CT: n=63 (23/40) 62.5±15.2 WS
Song (82) PNS: n=39 (12/27) N/A ≤48H WS
CT: n=39 (15/24) N/A WS
Ding et al. (83) PNS: n=15 (6/9) 55.1 (35–74) <48H WS
CT: n=17 (4/13) 57.7 (44–72) WS
Yuan et al. (84) PNS: n=67 (26/41) 59.2 (39–75) NR WS
CT: n=66 (27/39) 61.3 (41–75) WS
Ding and
Geng (85)
PNS: n=86 (34/52) 60.2±8.5 ≥7D HYTN
CT: n=86 (37/49) 61.4±8.2 HYTN
(Continued)
Authors Sample size (F/M) Average age
(range)
Disease
duration
Cause
Gao et al. (86) PNS: n=28 (12/16) 65.68±9.55 ≤24H WS
CT: n=24 (11/13) 65.88±9.47 WS
Chen (87) PNS: n=61 (23/38) 60.7±7.7
(38–74)
≥7D WS
CT: n=60 (19/41) 61.3±8.0 (36–75) WS
CT, current treatment; D, day; H, hour; HYTN, hypertension; N/A, not applica-
ble; NR, not reported; PNS, Panax notoginseng saponin; WS, wind stroke [Stroke
including hemorrhagic cerebrovascular accident (CVA), ischemic infarction CVA
and subarachnoid hemorrhage, etc. is often collectively referred to as wind stroke
in traditional Chinese medicine because of its sudden and acute onset, sudden
loss of consciousness with unilateral weakness, numbness, paralysis and dys-
phasia with or without experiencing unconsciousness, multiple symptoms and
rapid alterations in manifestations that are similar to the natural characteristics of
wind, which is changing rapidly].
to a small sample size (89) (MD= 14.87; 95% CI=−0.37, 30.11).
Analysis of the combined data showed significant statistical differ-
ence in IEV values between the PNS and CT groups (MD= 10.78;
95% CI= 9.07, 12.49; P < 0.00001) (Figure 5). On average, PNS
treatment reduced IEV value by about 50%.
Barthel index
The BI is a measure of functional disability and represents the
current quality of life (92). Only 2 trials of the 20 trials exam-
ined in this study reported BI (76, 83). The results showed
that PNS treatment significantly increased BI when compared
to the CT (MD= -11.73; 95% CI= -19.31, -4.16; P = 0.002)
(Figure 6). One trial involved 10 weeks of PNS treatment after
ICH and the result showed no significant difference in BI at
14 days after PNS treatment (P > 0.05), but significant differences
were observed at 28 days (P < 0.05) and 90 days after the treat-
ment (P < 0.01),suggesting that a relatively long course of PNS
treatment is necessary for significant improvement in functional
recovery (76).
Mortality rate
Figure 7 shows the results of meta-analyses on the NDP. Six trials
reported mortality data, showing that 48 of the 715 patients across
the six trials died (6.7%). The mortality of ICH patients was sig-
nificantly lower in the PNS group (13/361, or 3.6%) than in the
CT group (35/354, or 9.9%) (Peto OR= 2.78; 95% CI= 1.52, 5.08;
P = 0.0009). The trials were further divided into two subgroups
depending on the time of PNS intervention: (1) three trials that
started PNS treatment within 48 h of ICH onset (74, 84, 88) and
(2) four trials that started PNS treatment at or after 7 days of ICH
onset (72, 78, 87). One trial evaluated PNS intervention at both
48 h and 7 days after ICH onset (88). All trials assessed the mor-
tality at the end of the treatment course. The duration of PNS
treatment was 4 (72) and 6 (74) weeks, respectively, for 2 of the
trials, and was 2 weeks for the other trials. The results showed sig-
nificant reduction in the mortality of ICH patients treated with
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Table 2 | PNS treatment information of the 20 trials included in the meta-analyses.
Authors Interventions (sample size) Dosage Durations Observations Adverse incidences (%)
Guo et al. (90) PNS(n=100): XST Inj 200 mg/day 3 weeks ER NO
CT(n=100): MNT,ST NR
He et al. (89) PNS(n=12): XSHT Inj 140 mg/day 2 weeks IHV,IEV NR
CT(n=12): MNT,VC,KCI
Xu and Dong (72) PNS(n=42): XST FDP 400 mg/day 4 weeks ER,NDP NR
CT(n=40): DH,ICP,ST
Li et al. (88) PNS(n=55): XST Inj 600 mg/day 2 weeks ER,NDP,IHV Sr (5%)
CT(n=60): AHT,CICP,ST NO
Li and Yang (73) PNS(n=48): XST FDPI 400 mg/day) 2 weeks ER,NDS NO
CT(n=44): CAS NR
Tian et al. (74) PNS(n=36): XST Inj 200 mg/day 6 weeks ER,NDP,NDS,IHV NR
CT(n=30): MNT,FRS,ST
Li and Sun (75) PNS(n=29): XST Inj 500 mg/day 4 weeks ER NR
CT(n=31): DH,NTM,BCA,ST
Xie et al. (76) PNS(n=24): XSHT Inj 400 mg/day 10 weeks ER,BI NO
CT(n=22): DH,CICP,ST
Chen et al. (77) PNS(n=22): XST FDPI 800 mg/day 2 weeks NDS NO
CT(n=21): DH,CICP,AHT,ST
Dong and Wang (78) PNS(n=40): XST FDPI 400 mg/day 2 weeks ER,NDP NR
Zhang et al. (71) CT(n=38): DH,CICP,ST 2 weeks ER NO
PNS(n=65): LLT Inj 250 mg/day
CT(n=65): MNT, MGSO4,KCL,
INS, Aceglutamide Inj
Zhou et al. (79) PNS(n=70): XST FDPI 400 mg/day 2 weeks ER,NDS NR
CT(n=70): CICP,MNT,FRS Inj,
GFI,BCA,AHT,ST
Zheng (80) PNS(n=22): XSHT Inj 300 mg/day 3 weeks NDS NR
CT(n=19): ST
Tang et al. (81) PNS(n=63): XSHT Inj 300 mg/day 3 weeks IHV NR
CT(n=63): MNT,VC,ST
Song (82) PNS(n=39): XSHT Inj powder 450 mg/day 4 weeks IHV,IEV NR
CT(n=39): CICP, AHT,ST
Ding HY 2008 (83) PNS(n=15): XST FDPI 200 mg/day 2 weeks BI NR
CT(n=17):AHT, MNT,CICP, ST
Yuan HY 2008 (84) PNS(n=67): XST Inj 750 mg/day 2 weeks ER,NDP NO
CT(n=66): MNT,GFI NR
Ding and Geng (85) PNS(n=86): XSHT Inj 175 mg/day 3 weeks ER,IHV,IEV NO
CT(n=86): CICP, AHT,ST
Gao HY 2008 (86) PNS(n=28): XST Inj 250 mg/day 2 weeks NDS NR
CT(n=24): MNT,CICP, AHT,ST
Chen (87) PNS(n=61): SQZG 350 mg/day 2 weeks ER,NDP,IHV NR
CT(n=60): CICP, AHT,ST
AHT, anti-hypertensive treatment; BCA, brain cell activators; BI, Barthel index; CAS, citicoline sodium; CICP, control of intracerebral pressure; DH, dehydration; ER,
effectiveness rate; DPI, freeze-dry powder injector; FRS, furosemide; GFI, glycerol and fructose injection; IEV, intracerebral edema volume; IHV, intracerebral hematoma
volume; Inj, injection; INS, insulin; KCI, potassium chloride; MGSO4, magnesium sulfate; MNT, mannitol; NDP, number of death patients; NDS, neurological deficit
score; NR, not reported; NTM, neurotrophy medicine; PNS, Panax notoginseng saponin; CT, current treatment; SQZG, sanqi zaogan; Sr, skin rashes; ST, symptomatic
treatment; VC, vitamin C; XSHT, Xue Shuan Tong; XST, Xue Sai Tong (Xuesaitong).
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Table 3 | Detailed information of the hemorrhage sites of the 20 trials included in the meta-analyses.
Authors Sample size Intervention
time
Hematoma volume Sites of bleeding (cases)
Guo et al. (90) PNS(n=100) 3rd D 10–60 ml BGR (40),thalamus (20),lobar (33),cerebellar (7)
CT(n=100) BGR (42),thalamus (16),lobar (36),cerebellar (6)
He et al. (89) PNS(n=12) 5th D 10–30 ml UBG (12)
CT(n=12) UBG (12)
Xu and Dong (72) PNS(n=42) 10th–15th D <30 ml, 30–50 ml, >50 ml Putamen (18),thalamus (9), lobar (6),brainstem (6),cerebellar (3)
CT(n=40) Putamen (17),thalamus (8), lobar (7),brainstem (6),cerebellar (2)
Li et al. (88) A:PNS(n=60) ≤48H,≥7 D <42 ml A:BGR (46),FL (3),EC (1),IC (2),brainstem (3),
Ventricle (2), thalamus (1),cerebellar (2)
B:PNS(n=55) B:BGR (43),FL (2),EC (2),IC (3),brainstem (2),
Ventricle (1), cerebellar (2)
C:CT(n=60) C:BGR (45),FL (2),EC (2),IC (3),brainstem (3),
Ventricle (2), thalamus (1),cerebellar (2)
Li and Yang (73) PNS(n=48) 20th–22nd D <40 ml Lobar (12), EC or BG region (21), IC (9), ventricle (2), cerebellar (4)
CT(n=44) Lobar (10), EC or BG region (22), IC (8), ventricle (1), cerebellar (3)
Tian et al. (74) PNS(n=36) ≤48H ≤30 ml BGR (16), thalamus (11), lobar (9)
CT(n=30) BGR (13), thalamus (10), lobar (7)
Li and Sun (75) PNS(n=29) 1st–15th D 6–58 ml MBG (15), BGR (10), parietal lobe (2), FL (1),temporal (1)
CT(n=31) NR
Xie et al. (76) PNS(n=24) 3rd W SH≤30 ml, cerebellar≤15 ml, SH (20) cerebellar (3), brainstem (1)
Brainstem≤5 ml
CT(n=22) SH (17) cerebellar (4), brainstem (1)
Chen et al. (77) PNS(n=22) 2nd W ≤25 ml SH (22)
CT(n=21) SH (21)
Dong and Wang (78) PNS(n=40) 10th–15th D <30 ml, 30–50 ml, >50 ml Putamen (18),thalamus (8),lobar (5),brainstem (6),cerebellar (3)
CT(n=38) Putamen (17),thalamus (8),lobar (6),brainstem (5),cerebellar (2)
Zhang et al. (71) PNS(n=65) 3rd–8th D 30–50 ml NR
CT(n=65)
Zhou et al. (79) PNS(n=70) 4th–7th D 6–40 ml BG (48), lobar (17), cerebellar (5)
CT(n=70) BG (44), lobar (20), cerebellar (6)
Zheng (80) PNS(n=22) ≤48H <30 ml NR
CT(n=19)
Tang et al. (81) PNS(n=63) ≥3 D 10–40 ml NR
CT(n=63)
Song (82) PNS(n=39) ≤48H Low to medium SH 39
CT(n=39) SH 39
Ding et al. (83) PNS(n=15) ≤48H ≤30 ml BGR (15)
CT(n=17) BGR (17)
Yuan et al. (84) PNS(n=67) ≤48H 10–30 ml BGR (49), temporal (5),FL (7), OL (5), cerebellar (<5 ml) (1)
CT(n=66) BGR (47), temporal (6), FL (7), OL (3), cerebellar (<5 ml) (3)
Ding and Geng (85) PNS(n=86) ≥7 D Low to medium NR
CT(n=86)
Gao et al. (86) PNS(n=28) ≤48H <30 ml Thalamus (7),putamen (15),caudate nucleus (2),lobar (4)
CT(n=24) Thalamus (7),putamen (13),caudate nucleus (2),lobar (2)
Chen (87) PNS(n=61) ≥7 D ≤40 ml NR
CT(n=60)
BG, basal ganglia; BGR, basal ganglia region; CT, current treatment; EC, external capsule; FL, frontal lobe; IC, internal capsule; MBG, medial basal ganglia; OL, occipital
lobe; PNS, Panax notoginseng saponin; PL, parietal lobe; SH, supratentorial hemorrhage; UBG, unilateral basal ganglia.
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Study or Subgroup
1.1.1 2W, n=7
Yuan KZ 2010 [84]
Li H 2004 [75]
Li Q 2004 [73]
Xu YQ 2003 [72]
Dong YH 2006 [78]
Zhou YH 2007 [79]
Zhang Y 2007 [71]
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 4.85, df = 6 (P = 0.56); I² = 0%
Test for overall effect: Z = 6.02 (P < 0.00001)
1.1.2 3W, n=2
Yuan KZ 2010 [84]
Guo XF 2002 [90]
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.26, df = 1 (P = 0.61); I² = 0%
Test for overall effect: Z = 3.83 (P = 0.0001)
1.1.3 ≥4W, n=5
Chen KZ 2013 [87]
Li JM 2003 [88]
Xie GQ 2005 [76]
Ding HY 2010 [85]
Tian ZX 2004 [74]
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 7.16, df = 4 (P = 0.13); I² = 44%
Test for overall effect: Z = 5.49 (P < 0.00001)
Total (95% CI)
Total events
Heterogeneity: Chi² = 12.61, df = 13 (P = 0.48); I² = 0%
Test for overall effect: Z = 8.99 (P < 0.00001)
Test for subgroup differences: Chi² = 0.38, df = 2 (P = 0.83), I² = 0%
Events
40
17
40
35
33
47
63
275
48
72
120
43
22
17
72
26
180
575
Total
67
29
48
42
40
70
65
361
67
100
167
61
55
24
86
36
262
790
Events
31
12
28
25
23
22
55
196
36
49
85
37
15
8
47
9
116
397
Total
66
31
44
40
38
70
65
354
66
100
166
60
60
22
86
30
258
778
Weight
13.1%
5.0%
5.1%
4.4%
4.3%
7.5%
1.8%
41.2%
10.7%
14.3%
25.0%
11.5%
9.0%
2.5%
8.0%
2.8%
33.8%
100.0%
M-H, Fixed, 95% CI
1.67 [0.84, 3.32]
2.24 [0.80, 6.31]
2.86 [1.08, 7.59]
3.00 [1.07, 8.43]
3.07 [1.08, 8.73]
4.46 [2.19, 9.06]
5.73 [1.20, 27.27]
2.86 [2.03, 4.03]
2.11 [1.03, 4.32]
2.68 [1.49, 4.81]
2.43 [1.54, 3.83]
1.48 [0.70, 3.17]
2.00 [0.90, 4.43]
4.25 [1.23, 14.64]
4.27 [2.09, 8.70]
6.07 [2.08, 17.66]
2.87 [1.97, 4.18]
2.76 [2.21, 3.44]
PNS CT Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours CT Favours PNS
FIGURE 2 | Meta-analyses of the effectiveness rate (ER), comparing the
therapeutic effects of PNS injection with that of the current treatment
(CT). There is an overall significant statistical difference in ER between the
PNS and CT groups (P < 0.00001). And the differences in ER between the two
treatment groups were significant at 2, 3, and 4 weeks (P < 0.00001, each)
after PNS treatment. PNS, Panax notoginseng saponin; CT, Current treatment.
Study or Subgroup
Chen SL 2006 [77]
Gao Y 2011 [86]
Li Q 2004 [73]
Tian ZX 2004 [74]
Zheng XD 2007 [80]
Zhou YH 2007 [79]
Total (95% CI)
Heterogeneity: Chi² = 4.51, df = 5 (P = 0.48); I² = 0%
Test for overall effect: Z = 6.62 (P < 0.00001)
Mean
12.7
10.75
14.98
30.26
13
18.02
SD
9.58
4.93
9.87
8.34
9
7.36
Total
21
24
44
30
19
70
208
Mean
6.77
8
9.13
23.15
9
13.96
SD
8.71
4.24
8.72
7.53
5
5.13
Total
22
28
48
36
22
70
226
Weight
5.5%
26.2%
11.4%
11.1%
8.0%
37.7%
100.0%
IV, Fixed, 95% CI
5.93 [0.45, 11.41]
2.75 [0.23, 5.27]
5.85 [2.03, 9.67]
7.11 [3.24, 10.98]
4.00 [-0.55, 8.55]
4.06 [1.96, 6.16]
4.36 [3.07, 5.65]
CT PNS Mean Difference Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours CT Favours PNS
FIGURE 3 | Meta-analyses of the neurological deficit score (NDS). The overall effect showed significant statistical difference in NDS between the PNS and
CT groups (MD=4.36; 95% CI=3.07, 5.65; P < 0.00001). No heterogeneity (P =0.48) was found in NDS (6 trials). PNS, Panax notoginseng saponin; CT,
Current treatment.
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Study or Subgroup
1.3.1 4-7 Days n=6
Ding HY 2010 [85]
He D 2002 [89]
Li JM 2003 [88]
Song Y 2008 [82]
Tang YH 2007 [81]
Yuan KZ 2010 [84]
Subtotal (95% CI)
Heterogeneity: Tau² = 0.67; Chi² = 7.08, df = 5 (P = 0.21); I² = 29%
Test for overall effect: Z = 0.59 (P = 0.56)
1.3.2 10-14 Days n=3
Chen KZ 2013 [87]
Song Y 2008 [82]
Yuan KZ 2010 [84]
Subtotal (95% CI)
Heterogeneity: Tau² = 1.50; Chi² = 3.64, df = 2 (P = 0.16); I² = 45%
Test for overall effect: Z = 3.61 (P = 0.0003)
1.3.3 20-21 Days n=4
He D 2002 [89]
Tang YH 2007 [81]
Tian ZX 2004 [74]
Yuan KZ 2010 [84]
Subtotal (95% CI)
Heterogeneity: Tau² = 9.89; Chi² = 14.64, df = 3 (P = 0.002); I² = 80%
Test for overall effect: Z = 2.70 (P = 0.007)
1.3.4 28-40 Days n=4
Ding HY 2010 [85]
Li JM 2003 [88]
Song Y 2008 [82]
Tian ZX 2004 [74]
Subtotal (95% CI)
Heterogeneity: Tau² = 0.25; Chi² = 4.68, df = 3 (P = 0.20); I² = 36%
Test for overall effect: Z = 12.24 (P < 0.00001)
Test for subgroup differences: Chi² = 40.18, df = 3 (P < 0.00001), I² = 92.5%
Mean
32.03
24.75
23.54
30.02
26.3
21.6
10.28
18.98
13.4
6.15
12.58
9.87
12.2
6.03
6.11
5.03
4.76
SD
5.82
8.42
4.77
6.71
9.81
7.92
6.88
8.56
6.71
2.95
8.47
6.89
6.18
2.15
5.69
1.52
3.23
Total
86
12
55
39
63
67
322
61
39
67
167
12
63
36
67
178
86
55
39
36
216
Mean
31.25
25.28
23.19
33.27
27.8
21.6
13.63
25.09
15.9
10.1
20.23
16.79
13.4
11.56
10.12
10.78
8.57
SD
6.21
12.83
4.09
5.37
9.68
7.33
8.64
4.34
6.36
7.19
9.36
8.37
6.23
3.23
4.27
3.21
5.64
Total
86
12
60
39
63
66
326
60
39
66
165
12
63
36
66
177
86
60
39
36
221
Weight
26.2%
2.0%
29.1%
15.5%
10.8%
16.4%
100.0%
31.5%
28.7%
39.8%
100.0%
21.3%
25.6%
24.2%
28.8%
100.0%
41.4%
15.5%
30.7%
12.4%
100.0%
IV, Random, 95% CI
0.78 [-1.02, 2.58]
-0.53 [-9.21, 8.15]
0.35 [-1.28, 1.98]
-3.25 [-5.95, -0.55]
-1.50 [-4.90, 1.90]
0.00 [-2.59, 2.59]
-0.37 [-1.60, 0.87]
-3.35 [-6.14, -0.56]
-6.11 [-9.12, -3.10]
-2.50 [-4.72, -0.28]
-3.80 [-5.87, -1.74]
-3.95 [-8.35, 0.45]
-7.65 [-10.77, -4.53]
-6.92 [-10.46, -3.38]
-1.20 [-3.31, 0.91]
-4.82 [-8.32, -1.33]
-5.53 [-6.35, -4.71]
-4.01 [-5.86, -2.16]
-5.75 [-6.86, -4.64]
-3.81 [-5.93, -1.69]
-5.15 [-5.97, -4.32]
PNS CT Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours PNS Favours CT
FIGURE 4 | Meta-analyses of intracerebral hematoma volume (IHV)
among four subgroups with different time length of PNS treatment:
(1) the subtotal group of 6 trials with 4–7 days of PNS treatment
(Ding HY, He D, Li JM, SongY,TangYH,Yuan K) and, (2) the subgroup
of 3 trials with 10–14 days of treatment (Chen KZ, SongY,Yuan KZ)
showed no significant differences in IHV between PNS and CT
groups; (3) the subgroup of 4 trials with 20–21 days of PNS
treatment (He D,TangYH,Yuan KZ,Tian ZX) and, (4) the subgroup of
3 trials with 28–40 days of treatment [40, 78, 108,] (DingYH, Li JM,
SongY,Tian ZX) showed significant improvement in IHV in the PNS
group than in the CT group (P<0.00001, each). PNS, Panax
notoginseng saponin; CT, Current treatment.
Study or Subgroup
Ding HY 2010 [85]
He D 2002 [89]
Song Y 2008 [82]
Total (95% CI)
Heterogeneity: Chi² = 0.46, df = 2 (P = 0.80); I² = 0%
Test for overall effect: Z = 12.33 (P < 0.00001)
Mean
20.06
29.5
21.64
SD
8.46
26.1
9.49
Total
86
12
39
137
Mean
9.56
14.63
10.31
SD
4.45
6.66
4.57
Total
86
12
39
137
Weight
71.9%
1.3%
26.8%
100.0%
IV, Fixed, 95% CI
10.50 [8.48, 12.52]
14.87 [-0.37, 30.11]
11.33 [8.02, 14.64]
10.78 [9.07, 12.49]
PNS CT Mean Difference Mean Difference
IV, Fixed, 95% CI
-50 -25 0 25 50
Favours CT Favours PNS
FIGURE 5 | Results of meta-analyses on intracerebral edema volume (IEV) involving 3 trials. There was statistical difference in IEV values between PNS
and CT groups (MD=10.78; 95% CI=9.07, 12.49; P < 0.00001). PNS, Panax notoginseng saponin; CT, Current treatment.
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Study or Subgroup
Ding HY2008 [83]
Xie GQ 2005 [76]
Total (95% CI)
Heterogeneity: Chi² = 2.60, df = 1 (P = 0.11); I² = 61%
Test for overall effect: Z = 3.04 (P = 0.002)
Mean
90.3
60.31
SD
19.2
20.6
Total
17
22
39
Mean
97.3
80.23
SD
5.3
22.7
Total
15
24
39
Weight
63.4%
36.6%
100.0%
IV, Fixed, 95% CI
-7.00 [-16.51, 2.51]
-19.92 [-32.43, -7.41]
-11.73 [-19.31, -4.16]
CT PNS Mean Difference Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours PNS Favours CT
FIGURE 6 | Results of meta-analyses on Barthel index (BI) (2 trials). PNS treatment significantly increased BI compared to RT (MD= -11.73; 95%
CI= -19.31, -4.16; P =0.002). PNS, Panax notoginseng saponin; CT, Current treatment.
Study or Subgroup
1.6.1 ≤48h n=3
Li JM 2003 [88]
Tian ZX 2004 [74]
Yuan KZ 2010 [84]
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.48, df = 2 (P = 0.79); I² = 0%
Test for overall effect: Z = 1.97 (P = 0.05)
1.6.2 ≥7D n=4
Chen KZ 2013 [87]
Dong YH 2006 [78]
Li JM 2003 [88]
Xu YQ 2003 [72]
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 2.13, df = 3 (P = 0.55); I² = 0%
Test for overall effect: Z = 2.73 (P = 0.006)
Total (95% CI)
Total events
Heterogeneity: Chi² = 2.93, df = 6 (P = 0.82); I² = 0%
Test for overall effect: Z = 3.32 (P = 0.0009)
Test for subgroup differences: Chi² = 0.32, df = 1 (P = 0.57), I² = 0%
Events
14
1
2
17
2
1
14
1
18
35
Total
60
30
66
156
60
38
60
40
198
354
Events
7
0
1
8
1
1
2
1
5
13
Total
60
36
67
163
61
40
55
42
198
361
Weight
41.4%
2.4%
7.0%
50.8%
7.0%
4.7%
32.9%
4.7%
49.2%
100.0%
Peto, Fixed, 95% CI
2.23 [0.87, 5.69]
9.03 [0.18, 462.31]
2.00 [0.20, 19.55]
2.34 [1.00, 5.46]
2.00 [0.20, 19.63]
1.05 [0.06, 17.17]
5.11 [1.78, 14.63]
1.05 [0.06, 17.10]
3.31 [1.40, 7.83]
2.78 [1.52, 5.08]
PNS CT Peto Odds Ratio Peto Odds Ratio
Peto, Fixed, 95% CI
0.001 0.1 1 10 1000
Favours CT Favours PNS
FIGURE 7 | Meta-analyses of number of patients died (NDP) in
6 trials. The total number of patients died (NDP) was 48 out of 715
(6.7%). The mortality of ICH patients was significantly lower in PNS
group (13/361, 3.6%) than in CT group (35/354, 9.9%) (Peto OR=2.78;
95% CI=1.52, 5.08; P =0.0009). The trials were divided into two
subgroups based on the intervention time of PNS: (1) 3 trials with PNS
treatment started within 48 h after ICH onset (Li JM, Tian ZX, Yuan KZ),
(2) 4 trials with PNS treatment started 7 days from ICH onset [25, 41, 78,
131] (Chen KZ, Dong YH, Li JM, Xu YQ), One trial (LI JM) had trials
started both within 48 h and 7 days after ICH onset. All trials assessed
the mortality at the end of treatment course. Both PNS treatment
regimes significantly reduced the mortality of ICH patients compared to
the CT groups (P =0.05; P =0.006, respectively). PNS, Panax
notoginseng saponin; CT, Current treatment.
PNS within 48 h of ICH onset (Peto OR= 3.31; 95% CI= 1.40,
7.83; P = 0.006), but no significant differences between the PNS
and CT groups when PNS treatment started more than 48 h after
ICH onset (Peto OR= 2.34; 95% CI= 1.00, 5.46; P = 0.05), sug-
gesting that early PNS intervention is critical in reducing ICH
mortality.
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META-ANALYSIS ON SAFETY
Seven trials reported incidences of adverse events (73, 76, 77, 84,
85, 88, 90). Only one trial reported three cases of skin rashes related
to PNS injection (56). No severe side effects were reported in the
other six trials.
QUALITY ASSESSMENT
The quality assessment of the 20 included trials was evaluated
in accordance with Jadad’s scale. Four trials were assessed as high-
quality trials (scoring 3–5 marks) (76, 80, 88, 89), and the rest were
assessed as low-quality trials (scoring 1–2 marks) owing to poor
description on randomization and blindness in the papers. All tri-
als mentioned randomization and dropout rate but only three of
them described randomization methods (76, 80, 88) and one trial
mentioned single blinding in their methodological design (89).
FUNNEL PLOTS
To determine potential publication bias, funnel plot based on the
effective rate was elaborated (Figure 8). A total of 13 trials reported
the effect rate, which was categorized into three subgroups by the
treatment outcome evaluating time: (1) 7 trials assessed the ER
at the end of 2 weeks of treatment, (2) 2 trials assessed the ER at
the end of 3 weeks, and (3) 5 trials assessed the ER at the end of
4 weeks.
DISCUSSION
Intracerebral hemorrhage is the leading cause of death and disabil-
ity in people with TBI and stroke. So far, no proven drug is available
for ICH. From the meta-analysis of multiple clinical trials involv-
ing PNS treatment for intracerebral hemorrhage (ICH), we found
that ICH patients treated with PNS exhibited better outcomes
than ICH patients that received current treatments in all aspects
examined including the ER, the NDS, intracranial hematoma vol-
ume (IHV), intracranial edema volume (IEV), BI, and NDP. This
finding is consistent with the knowledge that P. notoginseng is an
effective medical herb for wound healing and bleeding.
INTERVENTION TIME
Because intracerebral bleeding is a major cause of mortality and
morbidity in ICH patients, timely intervention is critical for sav-
ing lives and for better outcomes of the patients. P. notoginseng is
a hemostatic drug that has been used to stop bleeding after gun-
shots and traumatic injuries since the Ming Dynasty (93). The
non-protein amino acid dencichine and notoginsenoside Ft1 of
PNS have been identified as the active hemostatic components of
P. notoginseng (17).
The timing of PNS intervention varied among the 20 clinical
trials examined. The earliest PNS intervention was given within
48 h of ICH onset (74, 80, 82, 84–86). These early treated patients
had the following common characteristics: hemorrhaging of less
than 30 ml, diagnosis of the precise bleeding site, no comas, and
stable vital signs. The last PNS intervention began 3 weeks after
ICH onset (73, 76). The majority of the patients, however, received
PNS between 1 and 2 weeks after ICH onset. Only one trial exam-
ined the timing effect of PNS intervention on the outcome of
ICH (88). In that trial, 60 ICH patients received 600 mg/day of
PNS within 24 h after ICH onset, and 55 ICH patients received
600 mg/day of PNS injection 7 days after ICH onset. Both treat-
ments lasted 14 days and both treatments improved the outcome
FIGURE 8 | A funnel plot was made using the data of effectiveness
rate (ER). A total of 13 trials reported the effect rate, which was
categorized into three subgroups by the evaluating time: (1) 7 trials
assessed the ER at the end of 2 weeks of treatment, (2) 2 trials assessed
the ER at the end of 3 weeks, and (3) 5 trials assessed the ER at the end
of 4 weeks. Because of the small number of trials involved, the imperfect
or asymmetrical funnel plot is not a reliable indication of potential
publication bias in this case.
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of the ICH patients compared to the CT groups. No difference was
found in the ER between the two PNS treatment groups (P > 0.5).
The results show that the death rate was two- to threefold lower
in ICH patients that received PNS treatment within 48 h of ICH
onset than those in the CT group (P = 0.05, Figure 6), suggesting
early PNS intervention can be critical for saving the lives of ICH
patients at risk of death.
Animal studies showed that PNS given at the third day of
acute cerebral hemorrhage produced the best effects in reduc-
ing cerebral edema and hematoma volume in rats when compared
to PNS administration given at other times (94). These authors
reported up regulation of Bcl-2 expression in cerebral tissue after
PNS treatment. Another animal model study showed that early
PNS treatment after ICH onset can significantly suppress brain
inflammation as reflected in reduced level of CAM-1 and TNF-α
expression in PNS-treated rats (95). Thus early PNS intervention
could minimize ICH-induced brain inflammation and neuronal
apoptosis, and facilitate the restoration of normal brain function.
ADVERSE EVENTS, DOSAGE, AND ROUTE OF ADMINISTRATION
Seven clinical trials included in this study reported the observation
of adverse events (73, 76, 77, 84, 85, 88, 90). Only three cases of
skin rash were reported after PNS (XST) injection in one trial (56),
accounting for 5.5% of the 55 PNS-treated patients of that trial
(Table 1). This finding is in agreement with our previous study
that the side effects of PNS use are relatively rare, with skin rash
being the most common side effect of PNS use, accounting for
more than 52% of all its adverse reactions (96).
There were considerable variations in the daily dose and total
dose of PNS administration among the 20 clinical trials included
in this study, with the lowest dose at 140 mg/day, the highest dose
at 800 mg/day, and the average dose at 373.25± 181.57 mg/day.
Most of the trials administered PNS at a dose range between 300
and 400 mg/day, with 12 trials at a dose greater than 300 mg/day.
So far, there is no consensus about the ideal daily dose and total
dose of PNS for ICH although 200–300 mg/day for 2–4 weeks are
usually recommended by the manufacturers of medical PNS.
For the treatment duration and the total dose, some studies
recommend a treatment course of 14 days (78), but others pro-
pose a 30–40-day treatment regime for achieving a better outcome
(74, 97). Of the 20 clinical trials included in this study, 1 trial
treated the ICH patients for 1 week, 2 trials for 11 weeks, 4 trials
for 3 weeks, 3 trials for 4 weeks, and 1 trial for 6 weeks (Table 1).
Our analysis shows that an increased duration of PNS treatment
is linked to a better outcome of the intracerebral hemotoma vol-
ume (Figure 4). Significant improvement in IHV was found only
after 10 or more days of PNS treatment. It appears that a mini-
mum of 2–4 weeks of treatment is required to achieve significant
improvement in the outcome of patients with acute ICH. A longer
treatment could bring additional benefit but with an additional
medical cost.
MORTALITY
Significantly reduced morbidity and mortality are the key indexes
of successful treatment of intracerebral hemorrhage. Of the 20
clinical trials, 3 trials reported short-term mortality in ICH
patients who received PNS treatment within 48 h after ICH onset
(74, 84, 88) (Figure 7), and 4 trials reported short-term mortal-
ity in ICH patients who received PNS treatment 7 days after ICH
onset (Figure 7). Both treatment regimens exhibited a more sig-
nificantly reduced the death rate in the PNS group than in the CT
group (by>2, P < 0.05, and>3-fold, P < 0.01, respectively). This
is consistent with a recent report that certain herbal ingredients of
traditional Chinese medicine (TCM) could stimulate the activa-
tion of blood, resolve hemostasis, and reduce acute ICH-induced
short-term mortality (10).
QUALITY OF LIFE
The quality of life of the ICH patients is closely associated with the
severity of the disease and the efficacy of the treatment (98, 99)
and is often assessed using the NDS and the BI. Of the 20 trials
included in the present study (with a total of 1,891 ICH patients),
only 2 trials measured BI (Figure 4) and reported improved activ-
ities of daily living in the PNS-treated ICH patients compared to
the patients in the CT group.
Neurological deficit score is an important index for the diag-
nosis of symptom severity and functional recovery of the patients.
Three of the trials included in this study reported NDS at 7, 15,
21, 28, and 30 days after PNS treatment (74, 77, 86) (Figure 2).
The results showed that it took at least 21 days for the PNS treat-
ment to produce noticeable improvements in ICH patients when
compared with the CT groups (74, 77, 86). That improvement in
terms of NDS, however, became significant at 28 days in one study
(86) and 40 days in another (74) after the start of PNS treatment
(P < 0.05, P < 0.01, respectively).
FUNNEL PLOTS
The funnel plot is often used to check for the existence of publica-
tion bias in meta-analyses, assuming that the largest studies will be
plotted near the average, and smaller studies will be spread evenly
on both sides of the average, creating a roughly funnel-shaped dis-
tribution. Deviation from this shape can indicate publication bias.
Although the funnel plot appeared asymmetrical in this study, it
may reflect the fact of unbalanced and very limited data of each
group (2W n= 7, 3W, n= 2, 4W, n= 5) (Figure 8) used for the
plot rather than a true publication bias as eight samples from
each group is considered minimal (while more than 20 is pre-
ferred) number required for a meaningful funnel plot, and a less
funnel plot may give a wrong impression of publication bias if
high precision studies are different from low precision studies with
respect to effect size (e.g., due to different populations examined)
(100). The appearance of the funnel plot can also alter substantially
depending on the scale on the y-axis (101).
MECHANISM OF PNS ACTION
Intracerebral hemorrhage can disrupt cerebral blood flow, energy
metabolism, and the integrity of the blood–brain barrier (BBB),
resulting in edema, inflammation, apoptosis, neurological dys-
function, and often death. Acute and chronic macro- and
micro-bleeding and thrombosis are the primary determinants of
hematoma and edema development. Agents that can effectively
control the bleeding and reduce hematoma and edema hold the
promise to become effective therapies for ICH and have been
the major treatment targets of multiple international ongoing
randomized control trials of ICH (102).
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Our meta-analysis shows that total P. notoginseng saponin
extract (PNS) could be a therapeutic agent for ICH because it
can significantly attenuate edema and hematoma in ICH patients.
This is in line with recent reports that PNS (XST) injection treat-
ment (175 mg/day) for 2 weeks significantly improved hematoma
absorption and neurological function in 32 acute ICH patients
compared to 29 RT controls (103). PNS has also been shown to
improve microcirculation around the hematoma ischemic area,
promote the absorption of hematoma, slow down and inhibit
brain edema development, and significantly shorten the time for
the edema to disappear (104).
The mechanism of PNS’ neuroprotection against ICH injury
remains to be fully understood. It may involve differential pro-
tective activities of various ginsenosides and notoginsenosides on
hemostasis, anti-coagulant, anti-thrombotic, platelet aggregation
and complement activation, hemorheology, blood viscosity and
hematocrit, vasodilation, microcirculation, energy metabolism,
oxidative stress, inflammation, and immune function. Some of
the recently published PNS actions are presented below as they
may be relevant or potential mechanisms of PNS in ICH.
HEMOSTATIC EFFECTS OF PNS
Spontaneous acute and chronic macro- and micro-bleeding con-
tribute directly to hematoma growth in TBI and ICH patients and
are linked with symptom severity, recurrence, and poor outcome
(105, 106). Preclinical TBI studies showed that the extent of ICH
acquired during acute and subacute phases (3 h, 3, 9, and 23 days)
post-ICH can predict the functional and histopathological out-
come in rats 6–12 months later and is correlated with the final
cortical atrophy (P < 0.05), hippocampal atrophy (P < 0.01), and
memory deficits (P < 0.01) (107).
At least two PNS components, i.e., dencichine and notogin-
senoside Ft1 have been identified to possess hemostatic properties
that could block or minimize bleeding and hematoma expansion
after ICH onset (17, 108). Dencichine is a bioactive non-protein
therapeutic amino acid found in P. notoginseng. At low concen-
trations, dencichine has hemostatic and platelet-enhancing activ-
ity, but at high concentrations, it is neurotoxic (108). Decichine
enhances hemostasis of activated platelets via AMPA receptors
(109). Notoginsenoside Ft1 is a potent procoagulant that can
induce dose-dependent and ADP-induced platelet aggregation,
increase plasma coagulation indexes, decrease tail-bleeding time,
and increase thrombogenesis and cytosolic Ca (2+) accumu-
lation. Dencichine and notoginsenoside Ft1 may underlie the
hemostatic mechanism of PNS during the acute and subacute
phases of ICH.
ANTI-THROMBOSIS, FIBRINOLYSIS, AND ANTI-COAGULATION
MECHANISM: ROLE OF NITRIC OXIDE
Patients with TBI and resultant intracranial hemorrhage (ICH)
are at high risk for developing venous thromboembolism (VTE)
(110). Intrahematomal blood clotting is also a pathogenetic fac-
tor in hyperacute perihematomal edema formation (111). There
is an increasing use of anti-platelets and/or anti-coagulants in the
treatment of blood clotting and hyperviscosity in ICH and there
is some evidence of therapeutic effects in animal models of ICH
(112–115). Several compounds of PNS including adenosine and
guanosine, ginsenoside Rh1, F1, Rg1, and Rg2 have anti-platelet
and anti-coagulant activities, with adenosine and guanosine and
the ginsenosides as the main anti-platelet aggregation compounds
of PNS (116–118).
One study showed that sanchinoside Rg1 markedly inhibited
experimental thrombosis formation by enhancing the function
of fibrinolysis system and stimulating vascular endothelial cells
to release nitric oxide (NO) (119). Ginsenoside Rb1 can also
reverse oxidative stress- and ischemia-related umbilical endothe-
lial dysfunction and myocardial injury through upregulation of
the endothelia NO synthase (eNOS) pathway in diabetes rat
model (120, 121).
PNS HAS ANTI-HYPERTENSION ACTIVITY
Hypertenison is a critical pathological factor in triggering
ICH onset. Notoginsenoside Ft1 activates both glucocorticoid
and estrogen receptors to induce endothelium-dependent, NO-
mediated relaxations in rat mesenteric arteries (122).
PNS INHIBITS COMPLEMENT ACTIVATION
PNS could improve the outcome of acute ICH by suppressing
the complement 3 (C3)-mediated pathway. Activation of comple-
ment cascades plays an important role in anaphylatoxin-mediated
inflammation, secondary toxicity, and brain damage after ICH
(24, 123). Studies have shown that PNS (co-)therapy inhibited
the enhancement of blood complement C3 levels in experimen-
tal ICH (86). Significant reduction in circulation complement
(C3) was found in 43 rheumatoid arthritis patients treated with
PNS for 28 days, and which was associated with improved clini-
cal symptoms such as joint swelling index when compared to the
control subjects (50). This could be a potential mechanism under-
lying the decreased volume of intracerebral edema in the patients
receiving PNS treatment group reported in the three clinical trials
(Figure 5). In ICH-induced local tissue inflammation, C3 pro-
motes the adhesion, exudation and translocation of inflammatory
cells, and stimulates the secretion of large amounts of inflamma-
tory mediators such as TNF-α and IL-1β, resulting in an increased
inflammatory response and brain damage. These responses are
absent in mice deficient in C3 activity and show reduced inflam-
matory cell infiltration, brain edema formation, and improved
neurologic outcome after experimental ICH (124, 125).
PNS PROTECTS BBB INTEGRATION
Blood–brain barrier disruption is a hallmark of ICH-induced
brain injury and contributes to edema formation, the influx of
leukocytes, and the entry of potentially neuroactive agents into the
perihematomal brain, all of which can contribute to brain injury.
Factors implicated in BBB disruption include: inflammatory medi-
ators (e.g., cytokines and chemokines), thrombin, hemoglobin
breakdown products, oxidative stress, complement proteins, and
matrix metalloproteinases, etc. (126, 127). Two studies have shown
that ginsenoside Rg1 provides neuroprotection against BBB dis-
ruption, edema formation, and neurological injury in rat models
of cerebral ischemia/reperfusion through the downregulation of
aquaporin 4 expression and anti-apoptosis pathways (38, 128).
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PNS PROTECTS AGAINST ISCHEMIA/REPERFUSION, AND STIMULATES
ANGIOGENESIS
Neurons are oxygen sensitive and are vulnerable to ischemic-
reperfusion injury after ICH. Experimental studies have shown
that PNS and ginsenosides Rb1 and Rb3 can provide signif-
icant protection against ischemia/reperfusion injury in rodent
brains (36, 129), cardiomyocytes (130, 131), and kidneys (132).
Ginsenoside Rb1 prevents homocysteine-induced endothelial dys-
function via PI3K/Akt activation and PKC inhibition (133). Gin-
senoside Rg1 enhances angiogenesis after hypoxia ischemia brain
damage in neonatal rats and in diabetic mice, in part through
hypoxia-inducible factor (HIF-1a), glucocorticoid receptor (GR),
and fibroblast growth factor receptor (VEGFR)-mediated path-
ways (134–138), and enhances the resistance of hematopoi-
etic stem/progenitor cells to radiation-induced aging in mice
(38). Notoginsenoside Ft1 promotes angiogenesis via HIF-1α
mediated VEGF secretion and the regulation of PI3K/AKT and
Raf/MEK/ERK signaling pathways (139). PNS also enhances
VEGF signals and promotes angiogenesis derived from rat bone
marrow and mesenchymal stem cells (140) as well as inhibit
ischemia-induced apoptosis by activating the PI3K/Akt pathway
in cardiomyocytes (141).
PNS STIMULATES STEM CELL PROLIFERATION AND DIFFERENTIATION
Cognitive impairment is common and is linked to neuronal
cell loss after ICH (92). PNS could promote functional recov-
ery of ICH patients through stimulating stem cell proliferation
and differentiation. Studies have shown that ginsenoside Rb1 can
improve spatial learning and memory by stimulating neurogenesis
in the hippocampal subregions of rats (22) and that ginseno-
side Rd can stimulate the proliferation of rat neural stem cells
in vivo and in vitro (28). Ginsenoside Rg1 stimulates the pro-
liferation and differentiation of human dental pulp stem cells
and facilitates neural differentiation of mouse embryonic stem
cells via the GR-dependent signaling pathway (31, 32), which
promotes peripheral nerve regeneration in the rat model of
nerve crush injury (142) and improves spatial learning-memory
in dementia rats after bone marrow mesenchymal stem cell
transplant (21). Ginsenoside Rg1 mediates microenvironment-
dependent endothelial differentiation of human mesenchymal
stem cells (143).
PNS PROTECTS MICROCIRCULATION FROM
ISCHEMIA/REPERFUSION-INDUCED INJURY
PNS treatment improved microcirculation around the hematoma
ischemic area, promoted the absorption of hematoma, slowed
down and inhibited brain edema development, and signifi-
cantly shortened the time for the edema to disappear (104).
Notoginsenoside R1 can attenuate ischemia/reperfusion (I/R)-
induced microvascular hyperpermeability, inflammatory cytokine
production, NF-kB activation, leukocyte rolling and adhesion,
the expression of E-selectin in endothelium and CD18 in neu-
trophils, loss of tight junction proteins, and deficit in energy
metabolism during I/R in rats (144, 145). Ginsenosides Rb1
and Rg1, and notoginsenoside R1 have been shown to protect
lipopolysaccharide-induced microcirculatory disturbance in rat
mesentery (146).
PNS HAS ROS-SCAVENGER, ANTIOXIDATION, AND ANTI-APOPTOSIS
PROPERTIES
PNS has been shown to be a potent antioxidant in various
experimental models. PNS induces thioredoxin-1 expression and
prevents 1-methyl-4-phenylpyridinium ion-induced neurotoxi-
city (147). Ginsenoside Rb1 directly scavenges hydroxyl rad-
icals and hypochlorous acid (103) and inhibits apoptosis in
hydrogen peroxide-treated chondrocytes by stabilizing mitochon-
dria and inhibiting Caspase-3 (148). Ginsenoside Rb1 also pre-
vented MPP(+)-induced apoptosis in PC12 cells by activating
estrogen receptors and ERK1/2/Akt pathways, and inhibiting
SAPK/JNK/p38 MAPK pathways (149). Ginsenoside Rb1 protects
against oxidative damage and renal interstitial fibrosis in rats with
unilateral ureteral obstruction (150), and against beta-amyloid
protein(1-42)-induced neurotoxicity in cortical neurons and in
PC12 cells (30, 33) as well as against hypoxia and oxidative stress
in rat retinal ganglion cells (29).
Ginsenoside Rd appears to be a superior neuroprotector with a
wide therapeutic window in experimental stroke (151). Ginseno-
side Rd attenuates redox imbalance, improves stroke outcome fol-
lowing focal cerebral ischemia in aged mice (152), and attenuates
early oxidative damage and sequential inflammatory responses
after transient focal ischemia in rats (153). Ginsenoside Rd pre-
vents glutamate-induced apoptosis in rat cortical neurons (154),
and promotes glutamate clearance by up-regulating the expres-
sion of glial glutamate transporter proteins (155). Ginsenoside-Rd
exhibits anti-inflammatory activities through the enhancement of
antioxidant enzyme activities and the inhibition of JNK and ERK
activation in vivo (156).
Ginsenoside Rg1 protects against hydrogen peroxide-induced
cell death in PC12 cells via the inhibition of NF-kB activation
(157), reduction of nigral iron levels in MPTP-treated C57BL6
mice by regulation of iron transport proteins (158), and protec-
tion against beta-amyloid peptide-induced human endothelial cel-
lapoptosis by activation of the GR-ERK signaling pathway (159).
Oral Rg1 supplementation strengthens the antioxidant defense
system against exercise-induced oxidative stress (160) and pro-
tects the liver against exhaustive exercise-induced oxidative stress
in rats (161).
PNS HAS ANTI-INFLAMMATION PROPERTIES
Ginsenoside Rbl shows anti-neuroinflammation effects in rat
models of Alzheimer’s disease (20) and prevents interleukin-1b-
induced inflammation and apoptosis in human articular chon-
drocytes (162). Ginsenoside Rd inhibits the expression of iNOS
and COX-2 by suppressing NF-kB in LPS-stimulated RAW264.7
cells and in mouse livers (163), and attenuates neuroinflammation
in cultured dopaminergic neurons (164). Ginsenoside Re amelio-
rates inflammation by inhibiting the binding of lipopolysaccha-
rides to TLR4 on macrophages (165). Ginsenoside Rg1 improves
survival in a murine model of polymicrobial sepsis by suppress-
ing the inflammatory response and apoptosis of lymphocytes
(166). Ginsenoside Rg1 improves streptozocin (STZ)-induced
diabetic nephropathy in rats by suppressing inflammatory reac-
tions and expression of ectodermal dysplasia and TGF-beta (167).
PNS also suppresses inflammation in a collagen-induced arthritis
model (146).
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ANTI-HYPERGLYCEMIA AND ANTI-HYPERLIPIDEMIC EFFECTS OF PNS
Hyperglycemia is associated with poor outcome in patients with
TBI and ICH and in experimental models of ICH (93, 168, 169).
PNS has hypolipidemic and antioxidant activities in rats with
high-fat diets (170). Ginsenoside Rb1 has antiobesity and anti-
hyperglycemic effects in rats (171). Ginsenoside Rb2 exerts its
antidiabetic effects via activation of AMPK (172). Ginsenoside Rb2
lowers cholesterol and triacylglycerol levels in 3T3-L1 adipocytes
under high cholesterol or fatty acids culture conditions (173). Gin-
senoside Re reverses insulin resistance in muscles of high-fat diet
rats (174). Ginsenoside Rg1 promotes glucose uptake through the
activated AMPK pathway in insulin-resistant muscle cells (175).
MANY COMPONENTS AND MANY MECHANISMS
Cerebral hemorrhage causes brain damage through multiple
mechanisms, with spontaneous bleeding, hematoma development
and perihematoma edema formation as the main factors con-
tributing to the poor outcome of ICH. Effective therapies for ICH
should be able to target all these factors. Our meta-analysis and
literature review suggest that PNS is an effective therapy for acute
ICH, and potentially functions through multiple mechanisms.
Its most notable effects include hemostatic and anti-thrombotic
effects, hemodynamic and hemorheological effects, angiogenesis
and stem cell promoting effects, anti-hyperglycemia and anti-
hyperlipidemia effects, and antioxidant and anti-inflammation
effects, etc. Additionally, the strong tonic effects of PNS (176) could
be beneficial to ICH patients,who are often weak and fragile during
the recovery phase. A double-blind, double-dummy, randomized,
and parallel-controlled study showed that 8 weeks after the onset
of cerebral infarction, treatment of PNS tablets for 4 weeks sig-
nificantly improved the outcome of the patients compared to the
control treatments (177).
There are limitations to this research. Not all of the clinical trials
analyzed were of high quality nor did they all include each desir-
able outcome evaluation. The number of ICH patients in each
trial was often less than 100 and no long-term outcome data of
the ICH patients were available. These and other factors should
be controlled in further large scale studies so that the therapeutic
effect of PNS can be better evaluated.
In conclusion, meta-analysis of the clinical trials suggests that
PNS is superior to current treatment for acute ICH with minimal
side effects. PNS could be an alternative therapy for acute ICH
patients with a hemorrhagic volume of less than 30 ml. More clin-
ical trials with better experimental designs could be conducted in
the US and Europe to verify and extend the current findings and to
determine the long-term effects of P. notoginseng on the recovery
and recurrence of ICH patients.
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